| Number of Journals | 8 |
| Number of Issues | 59 |
| Number of Articles | 440 |
| Article View | 161,006 |
| PDF Download | 105,588 |
Comparison of the Outcomes of the Two Surfactants, Beracsurf and Curosurf, in the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants | ||
| World Journal of Peri & Neonatology | ||
| Volume 8, Issue 1, May 2026 | ||
| Document Type: Original Article | ||
| Authors | ||
| Zoheir Fardid1; Seyed Reza Mirjalili1; Mahmood Noorishadkam1; Mahmood Vakili2; Maryam Saeida-Ardekani1; Mohamad Hosein Lookzadeh* 1 | ||
| 1Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| 2Department of Community and Preventive Medicine, Health Monitoring Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| Abstract | ||
| Background: Respiratory distress syndrome (RDS) in premature infants results from surfactant deficiency. Given the high cost and limited availability of Curosurf, we compared its outcomes with the Iranian surfactant Beracsurf. Methods: This descriptive cross-sectional study included premature infants (≤34 weeks) with RDS who met surfactant criteria. We assessed hospitalization duration, mechanical ventilation time, delivery mode, CPAP duration, Apgar score, gestational age, and clinical outcomes (discharge/mortality). Complications (pneumothorax, pulmonary/intraventricular hemorrhage, BPD, ROP, NEC), surfactant redosing frequency, and time to FiO₂<40% were compared between groups. Results: A total of 80 infants were divided into two equal groups (40 each). Baseline demographics were similar (P>0.05). Beracsurf recipients required significantly longer mechanical ventilation (3.25 vs. 2.22 days, P=0.01) and CPAP (3.05 vs. 2.41 days, P=0.04) than Curosurf recipients. No significant differences were observed in other complications, hospitalization duration, or mortality. Conclusion: Curosurf provided significantly shorter durations of respiratory support compared to Beracsurf. Other outcomes and complication rates were comparable. Further large-scale studies are warranted to guide clinical and economic decisions. | ||
| Keywords | ||
| Respiratory Distress Syndrome, Newborn; Infant, Premature; Pulmonary Surfactants; Beractant; Poractant Alfa; Treatment Outcome | ||
|
Statistics Article View: 1 |
||